Methamphetamine (MET) antibody and antigen (hapten, BSA/OVA conjugated)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-SMT-236-Ag01	BSA-Methamphetamine (MET)	756
GMP-SMT-236-Ag02	OVA-Methamphetamine (MET)	756
GMP-SMT-236-Ab01	Anti-human Methamphetamine (MET) mouse monoclonal antibody (mAb)	1953
GMP-SMT-236-Ab02	Anti-human Methamphetamine (MET) human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-SMT-236-Ag01
Product Name	BSA-Methamphetamine (MET)
Target/Biomarker	Methamphetamine (MET)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Methamphetamine (MET) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in MET level test of Pain () and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Methamphetamine (MET) / OVA-Methamphetamine (MET) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-236-Ag02
Product Name	OVA-Methamphetamine (MET)
Target/Biomarker	Methamphetamine (MET)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Methamphetamine (MET) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in MET level test of Pain () and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Methamphetamine (MET) / OVA-Methamphetamine (MET) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-236-Ab01
Product Name	Anti-human Methamphetamine (MET) mouse monoclonal antibody (mAb)
Target/Biomarker	Methamphetamine (MET)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Methamphetamine (MET) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in MET level test of Pain () and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Methamphetamine (MET) / OVA-Methamphetamine (MET) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-236-Ab02
Product Name	Anti-human Methamphetamine (MET) human monoclonal antibody (mAb)
Target/Biomarker	Methamphetamine (MET)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Methamphetamine (MET) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in MET level test of Pain () and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Methamphetamine (MET) / OVA-Methamphetamine (MET) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

1. Methamphetamine in In Vitro Diagnosis (IVD): An In-Depth Exploration Methamphetamine, a significant small molecule with multifaceted implications, occupies a prominent position in the landscape of in vitro diagnosis (IVD). This comprehensive examination delves into the pivotal role of Methamphetamine within IVD, elucidating its vital applications, methodologies, and the profound rationale behind its measurement. The intricate relationship between Methamphetamine and IVD unfolds as we explore its diverse applications and the scientific underpinnings that drive its relevance. 2. Methamphetamine's Role in Diagnostic Assays Methamphetamine serves as a linchpin in the development of diagnostic assays within IVD. Collaboratively employed with our specialized anti-small molecules antibodies and small molecules competitive antigens, Methamphetamine aids in achieving precise and specific detection and quantification of antibodies or immune responses specifically targeted against it. This strategic synergy forms the bedrock of IVD, enabling the identification and quantification of Methamphetamine-related phenomena with exceptional accuracy. 3. Clinical Surveillance and Methamphetamine Measurement Within the clinical realm, the measurement of Methamphetamine emerges as a matter of paramount importance. Methamphetamine is a potent central nervous system stimulant with a notable potential for abuse. Regular and systematic measurement of Methamphetamine levels within patient samples becomes a critical tool for monitoring individuals who may be engaged in illicit use of this substance. This surveillance is pivotal for early intervention, patient management, and the mitigation of potential health risks associated with Methamphetamine abuse. 4. Forensic and Workplace Testing The significance of Methamphetamine measurement extends beyond clinical applications to encompass forensic and workplace settings. Methamphetamine is a commonly screened substance in drug testing programs, where it is crucial to verify recent usage. The measurement of Methamphetamine in these contexts is fundamental for identifying individuals who have used this substance, ensuring compliance with regulatory requirements, and upholding organizational policies regarding substance use. 5. Treatment Monitoring and Rehabilitation In clinical settings, the measurement of Methamphetamine plays a vital role in monitoring patients undergoing addiction treatment or rehabilitation. Methamphetamine addiction is a challenging condition, and patients may struggle with relapse. Methamphetamine measurement allows healthcare providers to ascertain whether patients are adhering to treatment regimens and abstaining from Methamphetamine use during the recovery process. It empowers healthcare professionals to initiate tailored interventions when necessary, optimizing the chances of successful rehabilitation. 6. Personalized Medicine and Pharmacokinetics An in-depth understanding of Methamphetamine's pharmacokinetics is fundamental to the principles of personalized medicine. The quantification of Methamphetamine levels within patient samples empowers healthcare providers to customize treatment plans according to individual patient needs. By aligning Methamphetamine dosages precisely with physiological profiles, personalized medicine not only enhances therapeutic outcomes but also mitigates potential side effects or adverse reactions associated with suboptimal dosing. 7. Scientific Research and Advancements Beyond clinical applications, Methamphetamine measurement stands as a valuable asset in the realm of scientific research. Researchers leverage the insights gained from Methamphetamine measurement to advance our understanding of this substance's pharmacological properties, its effects on the human body, and potential treatments for Methamphetamine addiction. This research transcends the confines of clinical practice, contributing to broader discoveries in the field of healthcare and substance abuse. 8. Conclusion: The Comprehensive Significance of Methamphetamine Measurement in IVD In conclusion, the measurement of Methamphetamine within the context of in vitro diagnosis transcends its role as a mere diagnostic tool. It emerges as a linchpin in clinical surveillance, forensic and workplace testing, addiction treatment, personalized medicine, and scientific research. This comprehensive significance underscores its pivotal role in advancing healthcare outcomes, public safety, and our understanding of substance abuse. Methamphetamine measurement remains at the forefront of IVD, shaping the future of healthcare in multifaceted ways.

About GDU